Palvella Therapeutics (PVLA) Retained Earnings (2013 - 2026)
Palvella Therapeutics (PVLA) reported Retained Earnings of $95000.0 for Q1 2026, up 100.09% year-over-year from $47477.9 in Q1 2025, and up 100.07% quarter-over-quarter from -$135.4 million in Q4 2025.
Palvella Therapeutics (PVLA) Retained Earnings (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 14 years of Retained Earnings data on file, last reported at $95000.0 in Q1 2026.
- Retained Earnings for Q1 2026 came in at $95000.0, up 100.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $95000.0 (up 100.09% YoY), and the FY2025 annual result was -$135.4 million, down 4515100.0% from the prior year.
- Retained Earnings rose to $95000.0 in Q1 2026 per PVLA's latest filing, from -$135.4 million in the prior quarter.
- Over five years, Retained Earnings peaked at $953000.0 in Q1 2022 and troughed at -$326.3 million in Q3 2024.
- A 5-year average of -$162.4 million and a median of -$129.1 million in 2025 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings jumped 391.24% in 2022, then slumped 4515100.0% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$254000.0 in 2022, then slumped by 33.46% to -$339000.0 in 2023, then jumped by 100.88% to $3000.0 in 2024, then tumbled by 4515100.0% to -$135.4 million in 2025, then jumped by 100.07% to $95000.0 in 2026.
- Business Quant data shows PVLA's Retained Earnings at $95000.0 in Q1 2026, -$135.4 million in Q4 2025, and -$122.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | 95,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 95,000.00 |
| Dec 31, 2025 | -135.45 Mn |
| Sep 30, 2025 | -122.70 Mn |
| Jun 30, 2025 | -111.40 Mn |
| Mar 31, 2025 | -101.90 Mn |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | -326.30 Mn |
| Jun 30, 2024 | -323.45 Mn |
| Mar 31, 2024 | -319.86 Mn |
| Sep 30, 2023 | -339,000.00 |
| Jun 30, 2023 | -299.60 Mn |
| Mar 31, 2023 | -303.60 Mn |
| Dec 31, 2022 | -254,000.00 |
| Sep 30, 2022 | -282.30 Mn |
| Jun 30, 2022 | -272.60 Mn |
| Mar 31, 2022 | 953,000.00 |
| Dec 31, 2021 | -257.14 Mn |
| Sep 30, 2021 | 616,000.00 |
| Jun 30, 2021 | -231.10 Mn |
| Mar 31, 2021 | 194,000.00 |